Cutting-edge UK trials for mesothelioma: double immuno, arginine depletion and molecular profiling
Can checkpoint inhibitors combinations replace single agent drugs?
IMpower150 update from ELCC: atezolizumab and bevacizumab improve survival
The nurse's perspective on looking after lung cancer patients receiving immunotherapy
Results from the PACIFIC study: durvalumab with chemoradiation for the treatment of NSCLC